Expertise in
5
conditions

Hongyun T. Zhao

651 Dongfeng East Road, 
Guangzhou, CN 
Expertise in
5
conditions
651 Dongfeng East Road, 
Guangzhou, CN 

Overview

Hongyun Zhao practices practicing medicine in Guangzhou, China.

Zhao is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Nasopharyngeal Carcinoma.

They are actively involved in clinical research, co-authoring 181 peer reviewed articles and participating in 1 clinical trial.

Locations

651 Dongfeng East Road, Guangzhou, 510060, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase Ⅰ/Ⅰb Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Toripalimab (Anti-PD-1 Antibody) in Combination With Senaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors
A Phase Ⅰ/Ⅰb Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Toripalimab (Anti-PD-1 Antibody) in Combination With Senaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors
Enrollment Status: Withdrawn
Publish Date: September 21, 2022
Intervention Type: Drug
Study Phase: Phase 1

180 Total Publications

Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.
Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.
Journal: BMC cancer
Published: August 13, 2026

Frequently Asked Questions about Hongyun T. Zhao

Is Hongyun T. Zhao a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Hongyun T. Zhao is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hongyun T. Zhao participate in research or clinical trials?

Yes. Hongyun T. Zhao has published 180 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Hongyun T. Zhao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhao's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile